Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates

Journal of Biological Chemistry

Volumn 287, Issue 43, 2012, Pages 36473-36487

  Minond, Dmitriy ^a   Cudic, Mare ^a   Bionda, Nina ^a   Giulianotti, Marc ^a   Maida, Laura ^a   Houghten, Richard A ^a   Fields, Gregg B ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; BINDING COMPOUNDS; CHEMOTYPES; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; EXOSITE INTERACTIONS; EXOSITES; GLYCOSYLATED; HIGH THROUGHPUT SCREENING; IN-VIVO; KINETIC STUDY; METALLO-PROTEASE; RESEARCH TOOLS; SCHNEIDER; SCISSILE BOND; SUBSTRATE HYDROLYSIS; TUMOR NECROSIS FACTORS;

BIOASSAY; BIOCHIPS; ESTERIFICATION; GLYCOSYLATION; LIBRARIES; PROTEOLYSIS; SCAFFOLDS; ZINC;

SUBSTRATES;

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM8 PROTEIN; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; NEW DRUG; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYMATIC ASSAY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GLYCOSYLATION; HIGH THROUGHPUT SCREENING; IC 50; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN HYDROLYSIS;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION; HUMANS; HYDROLYSIS; MEMBRANE PROTEINS; PEPTIDE LIBRARY; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867781898     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.389114     Document Type: Article

References (74)

1. Houghten, R. A., Pinilla, C., Giulianotti, M. A., Appel, J. R., Dooley, C. T., Nefzi, A., Ostresh, J. M., Yu, Y., Maggiora, G. M., Medina-Franco, J. L., Brunner, D., and Schneider, J. (2008) Strategies for the use of mixture-based synthetic combinatorial libraries. Scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J. Comb. Chem. 10, 3-19
2. Pinilla, C., Appel, J. R., Borràs, E., and Houghten, R. A. (2003) Advances in the use of synthetic combinatorial chemistry. Mixture-based libraries. Nat. Med. 9, 118-122 (Pubitemid 36098272)
3. Moss, M. L., Stoeck, A., Yan, W., and Dempsey, P. J. (2008) ADAM10 as a target for anti-cancer therapy. Curr. Pharm. Biotechnol. 9, 2-8 (Pubitemid 351266964)
4. Kataoka, H. (2009) EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 56, 148-153
5. Moss, M. L., Sklair-Tavron, L., and Nudelman, R. (2008) Drug insight. Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4, 300-309 (Pubitemid 351791441)
6. Asai, M., Hattori, C., Szabó, B., Sasagawa, N., Maruyama, K., Tanuma, S., and Ishiura, S. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase. Biochem. Biophys. Res. Commun. 301, 231-235 (Pubitemid 36268873)
7. Kenny, P. A., and Bissell, M. J. (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. 117, 337-345 (Pubitemid 46203962)
8. Georgiadis, D., and Yiotakis, A. (2008) Specific targeting of metzincin family members with small-molecule inhibitors. Progress toward a multifarious challenge. Bioorg. Med. Chem. 16, 8781-8794
9. Edwards, D. R., Handsley, M. M., and Pennington, C. J. (2008) The ADAM metalloproteinases. Mol. Aspects Med. 29, 258-289
10. Fingleton, B. (2007) Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346
11. Dennis, M. S., Eigenbrot, C., Skelton, N. J., Ultsch, M. H., Santell, L., Dwyer, M. A., O'Connell, M. P., and Lazarus, R. A. (2000) Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 404, 465-470 (Pubitemid 30186881)
12. Roberge, M., Peek, M., Kirchhofer, D., Dennis, M. S., and Lazarus, R. A. (2002) Fusion of two distinct peptide exosite inhibitors of Factor VIIa. Biochem. J. 363, 387-393 (Pubitemid 34415776)
13. Roberge, M., Santell, L., Dennis, M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A. (2001) A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 40, 9522-9531 (Pubitemid 32757890)
14. Izaguirre, G., Rezaie, A. R., and Olson, S. T. (2009) Engineering functional antithrombin exosites in α1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa. J. Biol. Chem. 284, 1550-1558
15. Scheer, J. M., Romanowski, M. J., and Wells, J. A. (2006) A common allosteric site and mechanism in caspases. Proc. Natl. Acad. Sci. U.S.A. 103, 7595-7600
16. Hosseini, M., Jiang, L., Sørensen, H. P., Jensen, J. K., Christensen, A., Fogh, S., Yuan, C., Andersen, L. M., Huang, M., Andreasen, P. A., and Jensen, K. J. (2011) Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors, using non-natural arginine analogs. Mol. Pharmacol. 80, 585-597
17. Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C. F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H. K., and Dyer, R. D. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 282, 27781-27791 (Pubitemid 47529503)
18. Engel, C. K., Pirard, B., Schimanski, S., Kirsch, R., Habermann, J., Klingler, O., Schlotte, V., Weithmann, K. U., and Wendt, K. U. (2005) Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 12, 181-189 (Pubitemid 40281325)
19. Baragi, V. M., Becher, G., Bendele, A. M., Biesinger, R., Bluhm, H., Boer, J., Deng, H., Dodd, R., Essers, M., Feuerstein, T., Gallagher, B. M., Jr., Gege, C., Hochgurtel, M., Hofmann, M., Jaworski, A., Jin, L., Kiely, A., Korniski, B., Kroth, H., Nix, D., Nolte, B., Piecha, D., Powers, T. S., Richter, F., Schneider, M., Steeneck, C., Sucholeiki, I., Taveras, A., Timmermann, A., Van Veldhuizen, J., Weik, J., Wu, X., and Xia, B. (2009) A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis. Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 60, 2008-2018
20. Lauer-Fields, J. L., Minond, D., Chase, P. S., Baillargeon, P. E., Saldanha, S. A., Stawikowska, R., Hodder, P., and Fields, G. B. (2009) High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg. Med. Chem. 17, 990-1005
21. Roth, J., Minond, D., Darout, E., Liu, Q., Lauer, J., Hodder, P., Fields, G. B., and Roush, W. R. (2011) Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med. Chem. Lett. 21, 7180-7184
22. Wittwer, A. J., Hills, R. L., Keith, R. H., Munie, G. E., Arner, E. C., Anglin, C. P., Malfait, A. M., and Tortorella, M. D. (2007) Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (aggrecanase 1). Biochemistry 46, 6393-6401 (Pubitemid 46842882)
23. Yegneswaran, S., Tiefenbrunn, T. K., Fernandez, J. A., and Dawson, P. E. (2007) Manipulation of thrombin exosite I, by ligand-directed covalent modification. J. Thromb. Haemost. 5, 2062-2069 (Pubitemid 47450025)
24. Sela-Passwell, N., Rosenblum, G., Shoham, T., and Sagi, I. (2010) Structural and functional bases for allosteric control of MMP activities. Can it pave the path for selective inhibition? Biochim. Biophys. Acta 1803, 29-38
25. Rzychon, M., Chmiel, D., and Stec-Niemczyk, J. (2004) Modes of inhibition of cysteine proteases. Acta Biochim. Pol. 51, 861-873
26. Ishii, R., Minagawa, A., Takaku, H., Takagi, M., Nashimoto, M., and Yokoyama, S. (2007) The structure of the flexible arm of Thermotoga maritima tRNase Z differs from those of homologous enzymes. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63, 637-641 (Pubitemid 47205211)
27. Prudent, R., Sautel, C. F., and Cochet, C. (2010) Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. Biochim. Biophys. Acta 1804, 493-498
28. Pantke, M. M., Reif, A., Valtschanoff, J. G., Shutenko, Z., Frey, A., Weinberg, R. J., Pfleiderer, W., and Schmidt, H. H. (2001) Pterin interactions with distinct reductase activities of NO synthase. Biochem. J. 356, 43-51 (Pubitemid 34275704)
29. Vogel, A., Schilling, O., Späth, B., and Marchfelder, A. (2005) The tRNase Z family of proteins. Physiological functions, substrate specificity, and structural properties. Biol. Chem. 386, 1253-1264 (Pubitemid 41790808)
30. Gurard-Levin, Z. A., and Mrksich, M. (2008) The activity of HDAC8 depends on local and distal sequences of its peptide substrates. Biochemistry 47, 6242-6250 (Pubitemid 351812837)
31. Takeda, S., Igarashi, T., and Mori, H. (2007) Crystal structure of RVV-X. An example of evolutionary gain of specificity by ADAM proteinases. FEBS Lett. 581, 5859-5864 (Pubitemid 50008509)
32. Hall, T., Pegg, L. E., Pauley, A. M., Fischer, H. D., Tomasselli, A. G., and Zack, M. D. (2009) ADAM8 substrate specificity. Influence of pH on preprocessing and proteoglycan degradation. Arch. Biochem. Biophys. 491, 106-111
33. Tape, C. J., Willems, S. H., Dombernowsky, S. L., Stanley, P. L., Fogarasi, M., Ouwehand, W., McCafferty, J., and Murphy, G. (2011) Cross-domain inhibition of TACE ectodomain. Proc. Natl. Acad. Sci. U.S.A. 108, 5578-5583
34. Lauer-Fields, J. L., Minond, D., Sritharan, T., Kashiwagi, M., Nagase, H., and Fields, G. B. (2007) Substrate conformation modulates aggrecanase (ADAMTS-4) affinity and sequence specificity. Suggestion of a common topological specificity for functionally diverse proteases. J. Biol. Chem. 282, 142-150 (Pubitemid 47076608)
35. Minond, D., Lauer-Fields, J. L., Cudic, M., Overall, C. M., Pei, D., Brew, K., Moss, M. L., and Fields, G. B. (2007) Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry 46, 3724 -3733
36. Minond, D., Lauer-Fields, J. L., Cudic, M., Overall, C. M., Pei, D., Brew, K., Visse, R., Nagase, H., and Fields, G. B. (2006) The roles of substrate thermal stability and P2 and P1′ subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J. Biol. Chem. 281, 38302-38313 (Pubitemid 46041953)
37. Minond, D., Lauer-Fields, J. L., Nagase, H., and Fields, G. B. (2004) Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry 43, 11474-11481 (Pubitemid 39186968)
38. Caescu, C. I., Jeschke, G. R., and Turk, B. E. (2009) Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem. J. 424, 79-88
39. Moss, M. L., and Rasmussen, F. H. (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high throughput inhibitor screening. Anal. Biochem. 366, 144-148 (Pubitemid 46898217)
40. Moss, M. L., Rasmussen, F. H., Nudelman, R., Dempsey, P. J., and Williams, J. (2010) Fluorescent substrates useful as high-throughput screening tools for ADAM9. Comb. Chem. High Throughput Screen. 13, 358-365
41. Imperiali, B., and Rickert, K. W. (1995) Conformational implications of asparagine-linked glycosylation. Proc. Natl. Acad. Sci. U.S.A. 92, 97-101
42. Otvos, L., Jr., and Cudic, M. (2003) Conformation of glycopeptides. Mini Rev. Med. Chem. 3, 703-711
43. Bann, J. G., Peyton, D. H., and Bächinger, H. P. (2000) Sweet is stable: glycosylation stabilizes collagen. FEBS Lett. 473, 237-240 (Pubitemid 30254298)
44. Tagashira, M., Iijima, H., Isogai, Y., Hori, M., Takamatsu, S., Fujibayashi, Y., Yoshizawa-Kumagaye, K., Isaka, S., Nakajima, K., Yamamoto, T., Teshima, T., and Toma, K. (2001) Site-dependent effect of O-glycosylation on the conformation and biological activity of calcitonin. Biochemistry 40, 11090-11095 (Pubitemid 32847976)
45. Meldal, M., and Bock, K. (1994) A general approach to the synthesis of Oand N-linked glycopeptides. Glycoconj. J. 11, 59-63 (Pubitemid 24257169)
46. Takakura-Yamamoto, R., Yamamoto, S., Fukuda, S., and Kurimoto, M. (1996) O-Glycosylated species of natural human tumor necrosis factor-α. Eur. J. Biochem. 235, 431-437 (Pubitemid 26045457)
47. Bringman, T. S., Lindquist, P. B., and Derynck, R. (1987) Different transforming growth factor-α species are derived from a glycosylated and palmitoylated transmembrane precursor. Cell 48, 429-440 (Pubitemid 18095357)
48. Wollscheid, B., Bausch-Fluck, D., Henderson, C., O'Brien, R., Bibel, M., Schiess, R., Aebersold, R., and Watts, J. D. (2009) Mass spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat. Biotechnol. 27, 378-386
49. Martinez-Irujo, J. J., Villahermosa, M. L., Mercapide, J., Cabodevilla, J. F., and Santiago, E. (1998) Analysis of the combined effect of two linear inhibitors on a single enzyme. Biochem. J. 329, 689-698 (Pubitemid 28055195)
50. Copeland, R. (2000) Enzymes, 2nd Ed., pp. 289-290, Wiley-VCH, New York
51. Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., and Scheller, J. (2011) The soluble interleukin 6 receptor. Generation and role in inflammation and cancer. Eur. J. Cell Biol. 90, 484-494
52. Müllberg, J., Oberthür, W., Lottspeich, F., Mehl, E., Dittrich, E., Graeve, L., Heinrich, P. C., and Rose-John, S. (1994) The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J. Immunol. 152, 4958-4968 (Pubitemid 24139089)
53. Cole, A. R., Hall, N. E., Treutlein, H. R., Eddes, J. S., Reid, G. E., Moritz, R. L., and Simpson, R. J. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor. J. Biol. Chem. 274, 7207-7215
54. Wormald, M. R., Petrescu, A. J., Pao, Y. L., Glithero, A., Elliott, T., and Dwek, R. A. (2002) Conformational studies of oligosaccharides and glycopeptides. Complementarity of NMR, x-ray crystallography, and molecular modeling. Chem. Rev. 102, 371-386 (Pubitemid 35377620)
55. McManus, A. M., Otvos, L., Jr., Hoffmann, R., and Craik, D. J. (1999) Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative. Effects of glycosylation on solution conformation. Biochemistry 38, 705-714
56. Falenski, J. A., Gerling, U. I., and Koksch, B. (2010) Multiple glycosylation of de novo designed α-helical coiled coil peptides. Bioorg. Med. Chem. 18, 3703-3706
57. Zhao, Y. H., Abraham, M. H., and Zissimos, A. M. (2003) Fast calculation of van der Waals volume as a sum of atomic and bond contributions and its application to drug compounds. J. Org. Chem. 68, 7368-7373 (Pubitemid 37122487)
58. Patel, I. R., Attur, M. G., Patel, R. N., Stuchin, S. A., Abagyan, R. A., Abramson, S. B., and Amin, A. R. (1998) TNF-α convertase enzyme from human arthritis-affected cartilage. Isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-α. J. Immunol. 160, 4570-4579 (Pubitemid 28217317)
59. Huang, A., Joseph-McCarthy, D., Lovering, F., Sun, L., Wang, W., Xu, W., Zhu, Y., Cui, J., Zhang, Y., and Levin, J. I. (2007) Structure-based design of TACE selective inhibitors. Manipulations in the S1′-S3′ pocket. Bioorg. Med. Chem. 15, 6170-6181 (Pubitemid 47088960)
60. Healy, E. F., Romano, P., Mejia, M., and Lindfors, G., 3rd. (2010) Acetylenic inhibitors of ADAM10 and ADAM17. In silico analysis of potency and selectivity. J. Mol. Graph. Model. 29, 436-442
61. Bahia, M. S., and Silakari, O. (2010) Tumor necrosis factor α-converting enzyme. An encouraging target for various inflammatory disorders. Chem. Biol. Drug Des. 75, 415-443
62. Houghten, R. A., Pinilla, C., Appel, J. R., Blondelle, S. E., Dooley, C. T., Eichler, J., Nefzi, A., and Ostresh, J. M. (1999) Mixture-based synthetic combinatorial libraries. J. Med. Chem. 42, 3743-3778 (Pubitemid 29453457)
63. BalbÍn, M., Fueyo, A., Tester, A. M., Pendás, A. M., Pitiot, A. S., Astudillo, A., Overall, C. M., Shapiro, S. D., and López-Otin, C. (2003) Loss of collagenase- 2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35, 252-257
64. Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J. C., Agrawal, N. S., Lin, J. C., Westbroek, W., Hoogstraten-Miller, S., Molinolo, A. A., Fetsch, P., Filie, A. C., O'Connell, M. P., Banister, C. E., Howard, J. D., Buckhaults, P., Weeraratna, A. T., Brody, L. C., Rosenberg, S. A., and Samuels, Y. (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet. 41, 518 -520
65. Szabova, L., Chrysovergis, K., Yamada, S. S., and Holmbeck, K. (2008) MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 27, 3274-3281 (Pubitemid 351733384)
66. Wang, Z., Herzog, C., Kaushal, G. P., Gokden, N., and Mayeux, P. R. (2011) Actinonin, a meprin A inhibitor, protects the renal microcirculation during sepsis. Shock 35, 141-147
67. Becker-Pauly, C., Bruns, B. C., Damm, O., Schütte, A., Hammouti, K., Burmester, T., and Stöcker, W. (2009) News from an ancient world. Two novel astacin metalloproteases from the horseshoe crab. J. Mol. Biol. 385, 236-248
68. Santos, R. G., Giulianotti, M. A., Dooley, C. T., Pinilla, C., Appel, J. R., and Houghten, R. A. (2011) Use and implications of the harmonic mean model on mixtures for basic research and drug discovery. ACS Comb. Sci. 13, 337-344
69. Witters, L., Scherle, P., Friedman, S., Fridman, J., Caulder, E., Newton, R., and Lipton, A. (2008) Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 68, 7083-7089
70. Murumkar, P. R., DasGupta, S., Chandani, S. R., Giridhar, R., and Yadav, M. R. (2010) Novel TACE inhibitors in drug discovery. A review of patented compounds. Expert Opin. Ther. Pat. 20, 31-57
71. Letavic, M. A., Barberia, J. T., Carty, T. J., Hardink, J. R., Liras, J., Lopresti- Morrow, L. L., Mitchell, P. G., Noe, M. C., Reeves, L. M., Snow, S. L., Stam, E. J., Sweeney, F. J., Vaughn, M. L., and Yu, C. H. (2003) Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-α- converting enzyme inhibitors. Bioorg. Med. Chem. Lett. 13, 3243-3246 (Pubitemid 37093836)
72. Szardenings, A. K., Antonenko, V., Campbell, D. A., DeFrancisco, N., Ida, S., Shi, L., Sharkov, N., Tien, D., Wang, Y., and Navre, M. (1999) Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines. J. Med. Chem. 42, 1348-1357 (Pubitemid 29200870)
73. Njoroge, F. G., Vibulbhan, B., Pinto, P., Strickland, C., Bishop, W. R., Nomeir, A., and Girijavallabhan, V. (2006) Enhanced FTase activity achieved via piperazine interaction with catalytic zinc. Bioorg. Med. Chem. Lett. 16, 984-988 (Pubitemid 43059865)
74. Gooljarsingh, L. T., Lakdawala, A., Coppo, F., Luo, L., Fields, G. B., Tummino, P. J., and Gontarek, R. R. (2008) Characterization of an exosite binding inhibitor of matrix metalloproteinase 13. Protein Sci. 17, 66-71